Literature DB >> 24172059

The mechanisms of action of plasma exchange.

Hollie M Reeves1, Jeffrey L Winters.   

Abstract

The initial description of therapeutic plasma exchange (TPE) in an animal model was published almost 100 years ago. Since that time, this treatment has been applied to a wide variety of diseases but limited research has been published examining the mechanisms of action of TPE. The therapeutic effects of TPE could include the removal of pathological substances from the blood, such as monoclonal paraproteins and autoantibodies, as well as the replacement of deficient plasma components when plasma is used as a replacement fluid. Beyond these potential mechanisms, other possible mechanisms include possible alterations in lymphocyte proliferation and function that could sensitize these cells to immunosuppressant and chemotherapeutic agents and alterations in the immune system including changes in B and T cell numbers and activation, increased T suppressor function, and alteration in T-helper cell type 1/2 (Th1/Th2) ratio. Much remains unknown about the mechanisms of action of TPE, indicating a need for basic research into this therapy.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  apheresis; mechanism of action; plasma exchange; plasmapheresis

Mesh:

Year:  2013        PMID: 24172059     DOI: 10.1111/bjh.12629

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  47 in total

1.  Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis.

Authors:  Lidia Stork; David Ellenberger; Tim Beißbarth; Tim Friede; Claudia F Lucchinetti; Wolfgang Brück; Imke Metz
Journal:  JAMA Neurol       Date:  2018-04-01       Impact factor: 18.302

Review 2.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 3.  Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP).

Authors:  Jeffrey L Winters
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Successful treatment of a patient with severe atopic dermatitis and severe asthma by centrifugal therapeutic plasma exchange.

Authors:  Louise Fuller; Benit Maru; Neil Isserlis; Rino Cerio
Journal:  BMJ Case Rep       Date:  2015-05-12

Review 5.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

Review 6.  Immunological considerations-HLA matching and management of high immunological risk recipients.

Authors:  Olga Timofeeva; James Brown
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-07-29

7.  Changes of Thyroid Hormones and Their Binding Proteins during Plasma Exchange for Polyneuropathy in a Patient with Substituted Hypothyroidism due to Hashimoto's Thyroiditis.

Authors:  Stefan Jenni; Marcel Adler; Simone Lanz; Behrouz Mansouri Taleghani; Emanuel R Christ
Journal:  Transfus Med Hemother       Date:  2015-11-04       Impact factor: 3.747

8.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

9.  Immunoadsorption Column Reuse.

Authors:  Vaibhav Tiwari; Anurag Gupta; Smita Divyaveer; Vinant Bhargava; Manish Malik; Ashwani Gupta; Anil K Bhalla; D S Rana
Journal:  Indian J Nephrol       Date:  2020-11-07

10.  Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature.

Authors:  You-Wen Tan; Li Chen; Xing-Bei Zhou
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.